glp-1 cardiovascular outcome trials Effects and Tolerability of Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients Cardiovascular outcomes trials for GLP-1

Final Practical Takeaway Menstrual changes on GLP-1 are common, mostly reflect underlying hormonal normalization with weight loss, and generally stabilize within 6 months

Dehydration Risk Increases GLP-1 users often: eat less drink less feel less thirsty Alcohol: increases fluid loss increases electrolyte imbalance This can lead to: headaches fatigue constipation (already common on GLP-1s) dizziness Hydration becomes much more important

Your kitchen counter overnight, roughly 8 to 10 hours at maybe 72 degrees, barely registers on that timeline

What Makes GLP-1 Different

Given their clinical benefits and high price tags, GLP-1 RAs exemplify a tension in drug coverage: broad therapeutic value versus cost-containment

A network meta-analysis examining 105 randomized controlled trials with over 219,000 participants found no significant association between GLP-1 receptor agonists and increased infection risk, including urinary tract infections